[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100545018":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":10,"centralContacts":10,"locations":10,"responsibleParty":25,"collaborators":10,"id":29,"slug":30,"hasResults":31,"nctId":32,"briefTitle":33,"officialTitle":33,"acronym":10,"eligibilityCriteria":34,"healthyVolunteers":31,"sex":35,"minAge":36,"maxAge":37,"enrollmentInfo":38,"targetDuration":10,"studyType":41,"phases":10,"briefSummary":42,"conditions":43,"keywords":10,"overallStatus":45,"whyStopped":10,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":10},{"fullName":5,"class":6},"Hebei Medical University Fourth Hospital","OTHER",[8,13,16],{"label":9,"type":10,"description":10,"interventionNames":11},"Single drug group",null,[12],"Drug: Herombopag Olamine Tablets",{"label":14,"type":10,"description":10,"interventionNames":15},"combined rhTPO group",[12],{"label":17,"type":10,"description":10,"interventionNames":18},"combined IL-11 group",[12],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":10},"DRUG","Herombopag Olamine Tablets","Herombopag Olamine；combined rhTPO;combined IL-11",[9,17,14],{"type":26,"investigatorFullName":27,"investigatorTitle":28,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Jun wang","study principal investigator","100545018","a-multicentre-real-world-study-of-heptapopal-ethanolamine-tablets-in-concurrentsequential-radioimmunoinduced-thrombocytopenia-100545018",false,"NCT06376435","A Multicentre Real-world Study of Heptapopal Ethanolamine Tablets in Concurrent\u002FSequential Radioimmunoinduced Thrombocytopenia","Inclusion Criteria:\n\n* Understand the research procedure and voluntarily sign the informed consent to participate in the study\n* Subjects ≥18 years of age receiving synchronous\u002Fsequential chemotherapeutic therapy\n* Patients with platelet count ≤100×109\u002FL or platelet count decrease ≥ 50×109\u002FL or platelet count \\> 100×109\u002FL but need to be prophylaxis with hexapopethanolamine tablets\n* Researchers believe that subjects need to be treated with hexapopal.\n\nExclusion Criteria:\n\n* The subjects are conducting clinical intervention studies\n* Patients with known or expected allergy or intolerance to the active ingredient or excipient of hexapopar\n* Pregnant or lactating women\n* Other conditions deemed unsuitable for inclusion in the study by the researcher.","ALL","18 Years","75 Years",{"count":39,"type":40},500,"ESTIMATED","OBSERVATIONAL","The objective of this study was to observe and evaluate the efficacy and safety of hexapopal ethanolamine tablets in the treatment of synchronous\u002Fsequential radioimmunoinduced thrombocytopenia in the real world.\n\nThe subjects of this study were patients with solid malignant tumors who had received radioimmunoinduced thrombocytopenia.\n\nThis study will retrospectively and prospectively collect real-world data related to investigational drugs, and will observe 500 patients to observe the diagnosis and treatment pattern of radiochemo-induced thrombocytopenia. The study included a screening period (no more than one week) and a treatment period (at least two cycles).Participants meeting protocol inclusion criteria were defined as having platelet values \\\u003C 100×109\u002FL during radioimmunotherapy.",[44],"Cancer, Therapy-Related","NOT_YET_RECRUITING","2024-04-18",{"date":48,"type":49},"2024-04-19","ACTUAL",{"date":51,"type":40},"2024-04-20",{"date":53,"type":40},"2026-07-01",{"name":5,"class":6}]